Source: International Congress 2016 – Biomarkers and phenotypes of COPD
Disease area: Airway diseases



Rating:

Share or cite this content

Citations should be made in the following way:
Dieter Klopf (Nürnberg, Germany), Dieter Klopf, Johannes Rumpf, Peter Maier-Stocker, Kai Thomas, Christoph Koehl, Claudia Sommer, Peter Berg. Do inhaled corticosteroids reduce the frequent exacerbator phenotype in COPD - A little help by a multicenter survey. Eur Respir J 2016; 48: Suppl. 60, 3664

Member's Comments

No comment yet.

Related content which might interest you: MUC1-CT mediates corticosteroid responses in COPD Source: International Congress 2016 – Preclinical pharmacology: drug targets and mechanisms of action Year: 2016 Symptom profile of exacerbations in earlier and later COPD Source: Annual Congress 2013 –Asthma and COPD: diseases with different phenotypes Year: 2013 The effect on mortality of adding inhaled corticosteroids to long-acting bronchodilators for COPD: A focus on the frequent exacerbator phenotype Source: International Congress 2015 – COPD and lung function: risk factors and outcomes Year: 2015 QVA149 reduces COPD exacerbation rate in various subgroups of patients: The SPARK study Source: Annual Congress 2013 –New bronchodilators for COPD management Year: 2013 A global survey conducted to determine frequency of exacerbations in COPD patients Source: Annual Congress 2013 –COPD treatment Year: 2013 A pilot study of CPAP therapy for excessive dynamic airway collapse during acute exacerbation of COPD Source: International Congress 2014 – COPD - from biomarkers to novel therapeutic opportunities Year: 2014 Clinical and inflammatory characteristics of 'unreported' COPD exacerbations Source: Annual Congress 2013 –COPD mechanisms Year: 2013 Irisin is associated with severe exacerbations of COPD independently of lung function, comorbidities and exercise capacity Source: International Congress 2015 – Notable abstracts in COPD: variety Year: 2015 COPD on anti-GERD therapy remains at higher risk for severe exacerbation Source: International Congress 2014 – COPD exacerbations Year: 2014 Effect of exacerbation history and ICS use on outcomes in COPD patients from the TIOSPIR™ trial Source: International Congress 2015 – New data on established treatments for COPD Year: 2015 The role of IFN-γ in severe COPD patients with anamnestic viral-induced exacerbations before and after roflumilast treatment Source: International Congress 2016 – Translational studies in lung disease Year: 2016 Compare clinical effectiveness of various types of bronchodilators in COPD patients Source: International Congress 2016 – Novel avenues in the treatment of COPD I Year: 2016 Can antibiotics prevent acute COPD exacerbation? A systematic review and meta-analysis Source: Annual Congress 2013 –COPD: acute exacerbations and others Year: 2013 Are there any differences between Tunisian and European COPD phenotypes? Source: International Congress 2016 – Best abstracts in COPD management Year: 2016 Comparison of COPD patients with high and low symptoms from a real-world US survey Source: International Congress 2015 – Non-inflammatory monitoring of airway diseases Year: 2015 QVA149 improves lung function and reduces exacerbations compared to tiotropium in patients with severe-to-very severe COPD: The SPARK study Source: Annual Congress 2013 –Asthma and COPD management: novel clinical findings Year: 2013 Clinical characteristics of patients with frequent COPD exacerbations in a Swiss multicenter COPD cohort study (TOPDOCS) Source: International Congress 2016 – Targeting care, pulmonary rehabilitation, management, and self-management of COPD exacerbations in primary care Year: 2016 Eosinophilic airway inflammation as a complication of COPD, and the usefulness of ICS on these cases Source: International Congress 2016 – Novel avenues in the treatment of COPD I Year: 2016 Can we consider the "frequent exacerbator" a reliable COPD phenotype? Source: International Congress 2015 – COPD: chronic disease and comorbidities Year: 2015 Comparative study of hospitalized patients with acute exacerbation of COPD with and without carbon dioxide retention Source: Annual Congress 2013 –COPD treatment and others Year: 2013